Misplaced Pages

Rotavirus vaccine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

17°39′55″N 78°36′17″E  /  17.6652°N 78.6047°E  / 17.6652; 78.6047

#392607

70-579: The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized. The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where

140-459: A 10–11-year study of 657,461 children found that the MMR vaccine does not cause autism and actually reduced the risk of autism by seven percent. Beside the active vaccine itself, the following excipients and residual manufacturing compounds are present or may be present in vaccine preparations: Various fairly standardized abbreviations for vaccine names have developed, although the standardization

210-549: A G10P[12] lamb rotavirus strain. Rotasiil is a lyophilized pentavalent vaccine licensed for use in India in 2018. It contain human bovine reassortant strains of rotavirus serotypes G1, G2, G3, G4 and G9. This is world's first thermostable vaccine which can be stored without refrigeration at or below 25 °C. Rotasiil is manufactured by the Serum Institute of India . In 1998, a rotavirus vaccine (RotaShield, by Wyeth )

280-435: A broad immune response. Although most attenuated vaccines are viral, some are bacterial in nature. Examples include the viral diseases yellow fever , measles , mumps , and rubella , and the bacterial disease typhoid . The live Mycobacterium tuberculosis vaccine developed by Calmette and Guérin is not made of a contagious strain but contains a virulently modified strain called " BCG " used to elicit an immune response to

350-566: A complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue

420-729: A developmental COVID-19 vaccine named Covaxin , from the Drugs Controller General of India ( DCGI ), Government of India . The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis. A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate. In September 2020,

490-415: A given immune reaction. In some cases vaccines may result in partial immune protection (in which immunity is less than 100% effective but still reduces risk of infection) or in temporary immune protection (in which immunity wanes over time) rather than full or permanent immunity. They can still raise the reinfection threshold for the population as a whole and make a substantial impact. They can also mitigate

560-507: A national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation. Building trust and acceptance of a licensed vaccine among the public is a task of communication by governments and healthcare personnel to ensure a vaccination campaign proceeds smoothly, saves lives, and enables economic recovery. When a vaccine is licensed, it will initially be in limited supply due to variable manufacturing, distribution, and logistical factors, requiring an allocation plan for

630-453: A range of partners including governmental and non-governmental organisations to develop and implement mechanisms for providing access to this vaccine in the developing world, an effort which was slated to come to an end in 2020. Rotavac was licensed for use in India in 2014, and is manufactured by Bharat Biotech International Limited . It is a live attenuated, monovalent vaccine containing a G9P[11] human strain isolated from an Indian child. It

700-400: A strong immune response. When two or more vaccines are mixed in the same formulation, the two vaccines can interfere. This most frequently occurs with live attenuated vaccines, where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was first noted in the trivalent Sabin polio vaccine , where

770-682: A substantial impact, with rotavirus vaccine preventing 60% of cases against severe rotavirus and cutting emergency room visits in half. In the United States, vaccination has reduced rotavirus-related hospitalizations by as much as 86% since 2006. In April 2016, the World Health Organization released statistics for the period of 2000–2013, which showed developing countries that have introduced rotavirus vaccines experienced significant decreases in deaths and hospitalizations from rotavirus diarrhea after introduction. Additionally,

SECTION 10

#1732797896393

840-420: Is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates

910-549: Is a novel type of vaccine which is composed of the nucleic acid RNA, packaged within a vector such as lipid nanoparticles . Among the COVID-19 vaccines are a number of RNA vaccines to combat the COVID-19 pandemic and some have been approved or have received emergency use authorization in some countries. For example, the Pfizer-BioNTech vaccine and Moderna mRNA vaccine are approved for use in adults and children in

980-523: Is at the CDC's page called "Vaccine Acronyms and Abbreviations", with abbreviations used on U.S. immunization records. The United States Adopted Name system has some conventions for the word order of vaccine names, placing head nouns first and adjectives postpositively . This is why the USAN for " OPV " is "poliovirus vaccine live oral" rather than "oral poliovirus vaccine". A vaccine licensure occurs after

1050-711: Is available in many countries. Safety and efficacy trials in Africa and Asia found that the vaccines dramatically reduced severe disease among infants in developing countries, where a majority of rotavirus-related deaths occur. A 2021 Cochrane systematic review concluded that Rotavac, Rotateq, and Rotarix vaccines are safe and are effective at preventing diarrhea that is related to a rotavirus infection. Rotavirus vaccines are licensed in more than 100 countries, and more than 80 countries have introduced routine rotavirus vaccination. The incidence and severity of rotavirus infections has declined significantly in countries that have acted on

1120-438: Is by no means centralized or global. For example, the vaccine names used in the United States have well-established abbreviations that are also widely known and used elsewhere. An extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page. The page explains that "The abbreviations [in] this table (Column 3) were standardized jointly by staff of

1190-440: Is called herd immunity . Polio, which is transmitted only among humans, is targeted by an extensive eradication campaign that has seen endemic polio restricted to only parts of three countries (Afghanistan, Nigeria, and Pakistan). However, the difficulty of reaching all children, cultural misunderstandings, and disinformation have caused the anticipated eradication date to be missed several times. Vaccines also help prevent

1260-454: Is designed to immunize against a single antigen or single microorganism. A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. The valency of a multivalent vaccine may be denoted with a Greek or Latin prefix (e.g., bivalent , trivalent , or tetravalent/quadrivalent ). In certain cases, a monovalent vaccine may be preferable for rapidly developing

1330-524: Is encountered, the body recognizes the protein coat on the agent, and thus is prepared to respond, by first neutralizing the target agent before it can enter cells, and secondly by recognizing and destroying infected cells before that agent can multiply to vast numbers. Limitations to their effectiveness, nevertheless, exist. Sometimes, protection fails for vaccine-related reasons such as failures in vaccine attenuation, vaccination regimens or administration. Failure may also occur for host-related reasons if

1400-683: Is given by mouth in a three-dose series, four weeks apart, beginning at six weeks of age up until eight months of age. Rotavin-M1 was licensed for use in Vietnam in 2007, and is manufactured by the Center for Research and Production of Vaccines. The vaccine contains a G1P[8] human rotavirus strain. Lanzhou lamb rotavirus vaccine was licensed for use in China in 2000, and is manufactured by the Lanzhou Institute of Biological Products. It contains

1470-531: Is more effective against bacteria, has a better shelf-life, and improves vaccine stability, potency, and safety; but, in the U.S., the European Union , and a few other affluent countries, it is no longer used as a preservative in childhood vaccines, as a precautionary measure due to its mercury content. Although controversial claims have been made that thiomersal contributes to autism , no convincing scientific evidence supports these claims. Furthermore,

SECTION 20

#1732797896393

1540-575: Is prevented. The administration of vaccines is called vaccination . Vaccination is the most effective method of preventing infectious diseases; widespread immunity due to vaccination is largely responsible for the worldwide eradication of smallpox and the restriction of diseases such as polio , measles , and tetanus from much of the world. The World Health Organization (WHO) reports that licensed vaccines are currently available for twenty-five different preventable infections . The first recorded use of inoculation to prevent smallpox occurred in

1610-561: Is rarely associated with complications in immunodeficient individuals, and rotavirus vaccines are moderately associated with intussusception . At least 19 countries have no-fault compensation programs to provide compensation for those with severe adverse effects of vaccination. The United States' program is known as the National Childhood Vaccine Injury Act , and the United Kingdom employs

1680-467: Is the subunit vaccine against hepatitis   B , which is composed of only the surface proteins of the virus (previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast ). Other examples include the Gardasil virus-like particle human papillomavirus (HPV) vaccine, the hemagglutinin and neuraminidase subunits of

1750-651: The Vaccine Damage Payment . Vaccines typically contain attenuated, inactivated or dead organisms or purified products derived from them. There are several types of vaccines in use. These represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response. Some vaccines contain live, attenuated microorganisms. Many of these are active viruses that have been cultivated under conditions that disable their virulent properties, or that use closely related but less dangerous organisms to produce

1820-851: The influenza virus, and edible algae vaccines . A subunit vaccine is being used for plague immunization. Certain bacteria have a polysaccharide outer coat that is poorly immunogenic . By linking these outer coats to proteins (e.g., toxins), the immune system can be led to recognize the polysaccharide as if it were a protein antigen. This approach is used in the Haemophilus influenzae type B vaccine . Outer membrane vesicles (OMVs) are naturally immunogenic and can be manipulated to produce potent vaccines. The best known OMV vaccines are those developed for serotype B meningococcal disease . Heterologous vaccines also known as "Jennerian vaccines", are vaccines that are pathogens of other animals that either do not cause disease or cause mild disease in

1890-404: The 16th century in China, with the earliest hints of the practice in China coming during the 10th century. It was also the first disease for which a vaccine was produced. The folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Lady Mary Wortley Montagu . The terms vaccine and vaccination are derived from Variolae vaccinae (smallpox of the cow),

1960-522: The CDC further explains that "Upper-case letters in these abbreviations denote full-strength doses of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations. The 'a' in DTaP and Tdap stands for 'acellular', meaning that the pertussis component contains only a part of the pertussis organism." Another list of established vaccine abbreviations

2030-720: The Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP." Some examples are " DTaP " for diphtheria and tetanus toxoids and acellular pertussis vaccine, "DT" for diphtheria and tetanus toxoids, and "Td" for tetanus and diphtheria toxoids. At its page on tetanus vaccination,

2100-700: The FDA announced its decision to revoke the suspension, stating that porcine circovirus types 1 and 2 pose no safety risks in humans and concluded that health risks involved did not offset the benefits of the vaccination. In May 2010 the suspension of the Rotarix vaccine was lifted. Doctors Without Borders (MSF) developed a heat-stable version named BRV-PV. Phase 3 of the clinical trials were completed in Niger on 31 December 2020. The vaccine has been associated with lower rates of type 1 diabetes . Vaccine A vaccine

2170-515: The US FDA in April 2008. It is taken by mouth . Rotateq is a live, oral pentavalent vaccine that contains five rotavirus strains produced by reassortment . The rotavirus   A parent strains of the reassortants were isolated from human and bovine hosts. Four reassortant rotaviruses express one of the outer capsid, VP7, proteins (serotypes G1, G2, G3, or G4) from the human rotavirus parent strain and

Rotavirus vaccine - Misplaced Pages Continue

2240-489: The US. A DNA vaccine uses a DNA plasmid (pDNA)) that encodes for an antigenic protein originating from the pathogen upon which the vaccine will be targeted. pDNA is inexpensive, stable, and relatively safe, making it an excellent option for vaccine delivery. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability,

2310-469: The absence of any infectious agent and the relative ease of large-scale manufacture. Many innovative vaccines are also in development and use. While most vaccines are created using inactivated or attenuated compounds from microorganisms, synthetic vaccines are composed mainly or wholly of synthetic peptides, carbohydrates, or antigens. Vaccines may be monovalent (also called univalent ) or multivalent (also called polyvalent ). A monovalent vaccine

2380-479: The amount of serotype   2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype   1 and   3 viruses in the vaccine. It was also noted in a 2001 study to be a problem with dengue vaccines, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, -2 and -4 serotypes. Vaccines typically contain one or more adjuvants , used to boost

2450-628: The attachment protein VP4 (type P7) from the bovine rotavirus parent strain. The fifth reassortant virus expresses the attachment protein VP4, (type P1A), from the human rotavirus parent strain and the outer capsid protein VP7 (serotype G6) from the bovine rotavirus parent strain. In February 2006, the US Food and Drug Administration (FDA) approved Rotateq for use in the United States. In August 2006, Health Canada approved Rotateq for use in Canada. Merck worked with

2520-482: The body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (to prevent or alleviate the effects of a future infection by a natural or "wild" pathogen ), or therapeutic (to fight a disease that has already occurred, such as cancer ). Some vaccines offer full sterilizing immunity , in which infection

2590-445: The company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop a COVID-19 vaccine. In May 2020, Indian Council of Medical Research's ( ICMR 's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine. On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for

2660-467: The company has over 700 employees and has a presence worldwide. The company has been responsible for developing an eco-friendly recombinant and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC. They were one of the first to develop vaccines for viral diseases like Chikungunya and Zika . The company also produces vaccines for Japanese Encephalitis . Bharat Biotech has biosafety level 3 (BSL3) laboratories. In April 2020,

2730-503: The development of antibiotic resistance. For example, by greatly reducing the incidence of pneumonia caused by Streptococcus pneumoniae , vaccine programs have greatly reduced the prevalence of infections resistant to penicillin or other first-line antibiotics. The measles vaccine is estimated to prevent a million deaths every year. Vaccinations given to children, adolescents, or adults are generally safe. Adverse effects, if any, are generally mild. The rate of side effects depends on

2800-535: The disease is common. This should be done along with promoting breastfeeding , handwashing, clean water, and good sanitation. It is given by mouth and requires two or three doses. The vaccines are safe. This includes their use in people with HIV/AIDS . The vaccines are made from weakened rotavirus . The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines . The vaccine

2870-425: The eradication of smallpox , one of the most contagious and deadly diseases in humans. Other diseases such as rubella, polio , measles, mumps, chickenpox , and typhoid are nowhere near as common as they were a hundred years ago thanks to widespread vaccination programs. As long as the vast majority of people are vaccinated, it is much more difficult for an outbreak of disease to occur, let alone spread. This effect

Rotavirus vaccine - Misplaced Pages Continue

2940-416: The finished product, as they may in the environment and population as a whole. Many vaccines need preservatives to prevent serious adverse effects such as Staphylococcus infection, which in one 1928 incident killed 12 of 21 children inoculated with a diphtheria vaccine that lacked a preservative. Several preservatives are available, including thiomersal, phenoxyethanol , and formaldehyde . Thiomersal

3010-483: The first dose of vaccine be given right after six weeks of age. Rotarix is a monovalent, human, live attenuated rotavirus vaccine containing one rotavirus strain of G1P[8] specificity. Rotarix is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series in infants and children. It was approved in the European Union in 2006, and by

3080-557: The general population, a high standard of safety is required. As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process. Vaccine manufacturers do not receive licensing until

3150-434: The host can still become infected. Once antibodies are produced, they may promote immunity in any of several ways, depending on the class of antibodies involved. Their success in clearing or inactivating a pathogen will depend on the amount of antibodies produced and on the extent to which those antibodies are effective at countering the strain of the pathogen involved, since different strains may be differently susceptible to

3220-414: The host's immune system does not respond adequately or at all. Host-related lack of response occurs in an estimated 2-10% of individuals, due to factors including genetics, immune status, age, health and nutritional status. One type of primary immunodeficiency disorder resulting in genetic failure is X-linked agammaglobulinemia , in which the absence of an enzyme essential for B cell development prevents

3290-411: The host's immune system from generating antibodies to a pathogen . Host–pathogen interactions and responses to infection are dynamic processes involving multiple pathways in the immune system. A host does not develop antibodies instantaneously: while the body's innate immunity may be activated in as little as twelve hours, adaptive immunity can take 1–2 weeks to fully develop. During that time,

3360-417: The immune response. Tetanus toxoid, for instance, is usually adsorbed onto alum . This presents the antigen in such a way as to produce a greater action than the simple aqueous tetanus toxoid. People who have an adverse reaction to adsorbed tetanus toxoid may be given the simple vaccine when the time comes for a booster. In the preparation for the 1990 Persian Gulf campaign, the whole cell pertussis vaccine

3430-430: The immunodominant antigen of the pathogen or a surface protein that enables the formation of neutralizing antibodies. The subgroup of genetic vaccines encompass viral vector vaccines, RNA vaccines and DNA vaccines. Viral vector vaccines use a safe virus to insert pathogen genes in the body to produce specific antigens , such as surface proteins , to stimulate an immune response . An mRNA vaccine (or RNA vaccine )

3500-573: The limited supply and which population segments should be prioritized to first receive the vaccine. Bharat Biotech Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad , which is engaged in drug discovery , drug development , and the manufacture of vaccines , biotherapeutics , pharmaceuticals and healthcare products. Bharat Biotech has its manufacturing facility situated at Genome Valley , Hyderabad , India. As of July 2020,

3570-414: The market in 1999. There then followed eight years of delay until rival manufacturers were able to introduce new vaccines that were shown to be more safe and effective in children: Rotarix by GlaxoSmithKline and Rotateq by Merck . Both are taken orally and contain disabled live virus. The World Health Organization recommends that rotavirus vaccine be included in all national immunization schedules because

SECTION 50

#1732797896393

3640-448: The microorganism. Examples of toxoid-based vaccines include tetanus and diphtheria . Not all toxoids are for microorganisms; for example, Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites. Rather than introducing an inactivated or attenuated microorganism to an immune system (which would constitute a "whole-agent" vaccine), a subunit vaccine uses a fragment of it to create an immune response. One example

3710-407: The new protective inoculations then being developed. The science of vaccine development and production is termed vaccinology . There is overwhelming scientific consensus that vaccines are a very safe and effective way to fight and eradicate infectious diseases. The immune system recognizes vaccine agents as foreign, destroys them, and "remembers" them. When the virulent version of an agent

3780-440: The number of cases dropped to fewer than 150 per year (median of 56). In early 2008, there were 64 suspected cases of measles. Fifty-four of those infections were associated with importation from another country, although only thirteen percent were actually acquired outside the United States; 63 of the 64 individuals either had never been vaccinated against measles or were uncertain whether they had been vaccinated. Vaccines led to

3850-494: The only childhood vaccine in the U.S. that contains thiomersal in greater than trace amounts is the influenza vaccine, which is currently recommended only for children with certain risk factors. Single-dose influenza vaccines supplied in the UK do not list thiomersal in the ingredients. Preservatives may be used at various stages of the production of vaccines, and the most sophisticated methods of measurement might detect traces of them in

3920-400: The organism being treated. The classic example is Jenner's use of cowpox to protect against smallpox. A current example is the use of BCG vaccine made from Mycobacterium bovis to protect against tuberculosis . Genetic vaccines are based on the principle of uptake of a nucleic acid into cells, whereupon a protein is produced according to the nucleic acid template. This protein is usually

3990-418: The recommendation to introduce the rotavirus vaccine. In Mexico, which in 2006 was among the first countries in the world to introduce rotavirus vaccine, the diarrheal disease death rates from rotavirus dropped by more than 65% among children age two and under during the 2009 rotavirus season. In Nicaragua, which in 2006 became the first developing country to introduce the rotavirus vaccine, investigators recorded

4060-578: The risk of intussusception following rotavirus vaccination remains very low compared with the benefits of preventing the impact of severe and deadly diarrhoea. A 2009 review estimated that vaccination against rotavirus would prevent about 45% of deaths due to rotavirus gastroenteritis, or about 228,000 deaths annually worldwide. At US$ 5 per dose, the estimated cost per life saved was $ 3,015, $ 9,951 and $ 11,296 in low-, lower-middle-, and upper-middle-income countries, respectively. More than 80 countries have introduced routine rotavirus vaccination, almost half with

4130-437: The severity of infection and response to a vaccine. Elderly (above age 60), allergen-hypersensitive , and obese people have susceptibility to compromised immunogenicity , which prevents or inhibits vaccine effectiveness, possibly requiring separate vaccine technologies for these specific populations or repetitive booster vaccinations to limit virus transmission . Severe side effects are extremely rare. Varicella vaccine

4200-457: The severity of infection, resulting in a lower mortality rate , lower morbidity , faster recovery from illness, and a wide range of other effects. Those who are older often display less of a response than those who are younger, a pattern known as Immunosenescence . Adjuvants commonly are used to boost immune response, particularly for older people whose immune response to a simple vaccine may have weakened. The efficacy or performance of

4270-496: The successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases   I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated). Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among

SECTION 60

#1732797896393

4340-615: The support of Gavi, the Vaccine Alliance . In March 2010, the detection of DNA from porcine circovirus types 1 and 2 within Rotateq and Rotarix prompted the FDA to suspend the use of rotavirus vaccines while conducting an investigation the finding of DNA from porcine circovirus-1 (PCV1) in the vaccine in collaboration with the 12 members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). On 6 May 2010,

4410-520: The term devised by Edward Jenner (who both developed the concept of vaccines and created the first vaccine) to denote cowpox . He used the phrase in 1798 for the long title of his Inquiry into the Variolae vaccinae Known as the Cow Pox , in which he described the protective effect of cowpox against smallpox. In 1881, to honor Jenner, Louis Pasteur proposed that the terms should be extended to cover

4480-574: The vaccine in question. Some common side effects include fever, pain around the injection site, and muscle aches. Additionally, some individuals may be allergic to ingredients in the vaccine. MMR vaccine is rarely associated with febrile seizures . Host-("vaccinee")-related determinants that render a person susceptible to infection, such as genetics , health status (underlying disease, nutrition, pregnancy, sensitivities or allergies ), immune competence , age, and economic impact or cultural environment can be primary or secondary factors affecting

4550-413: The vaccine is dependent on several factors: If a vaccinated individual does develop the disease vaccinated against ( breakthrough infection ), the disease is likely to be less virulent than in unvaccinated cases. Important considerations in an effective vaccination program: In 1958, there were 763,094 cases of measles in the United States; 552 deaths resulted. After the introduction of new vaccines,

4620-495: The vaccine were 30 times more likely to develop a severe form of bowel obstruction, called intussusception, during 3 to 7 days after the first dose than unvaccinated infants. The excess risk was estimated between one case in 5,000 to 10,000 vaccinees. Based on these data, the Advisory Committee on Immunization Practices (ACIP) withdraw recommendation to use the vaccine, and the manufacturer of the vaccine withdrew it from

4690-777: The vaccine. The live attenuated vaccine containing strain Yersinia pestis EV is used for plague immunization. Attenuated vaccines have some advantages and disadvantages. Attenuated, or live, weakened, vaccines typically provoke more durable immunological responses. But they may not be safe for use in immunocompromised individuals, and on rare occasions mutate to a virulent form and cause disease. Some vaccines contain microorganisms that have been killed or inactivated by physical or chemical means. Examples include IPV ( polio vaccine ), hepatitis A vaccine , rabies vaccine and most influenza vaccines . Toxoid vaccines are made from inactivated toxic compounds that cause illness rather than

4760-442: The vaccines may also prevent illness in non-vaccinated children by limiting exposure through the number of circulating infections. A 2014 review of available clinical trial data from countries routinely using rotavirus vaccines in their national immunization programs found that rotavirus vaccines have reduced rotavirus hospitalizations by 49–92% and all-cause diarrhea hospitalizations by 17–55%. The World Health Organization recommends

4830-578: Was licensed for use in the United States. Clinical trials in the United States, Finland , and Venezuela had found it to be 80 to 100% effective at preventing severe diarrhea caused by rotavirus   A, and researchers had detected no statistically significant serious adverse effects. However post-licensure studies conducted in the United States by Trudy Murphy and her colleagues at the Centers For Disease Control and Prevention (CDC) and Kramarz et al., found that Infants who received

4900-448: Was used as an adjuvant for anthrax vaccine. This produces a more rapid immune response than giving only the anthrax vaccine, which is of some benefit if exposure might be imminent. Vaccines may also contain preservatives to prevent contamination with bacteria or fungi . Until recent years, the preservative thiomersal ( a.k.a. Thimerosal in the US and Japan) was used in many vaccines that did not contain live viruses. As of 2005,

#392607